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Abstract: The history of phage therapy started with its first clinical application in 1919 and continues
its development to this day. Phages continue to lack any market approval in Western medicine
as a recognized drug, but are increasingly used as an experimental therapy for the compassionate
treatment of patients experiencing antibiotic failure. The few formal experimental phage clinical
trials that have been completed to date have produced inconclusive results on the efficacy of phage
therapy, which contradicts the many successful treatment outcomes observed in historical accounts
and recent individual case reports. It would therefore be wise to identify why such a discordance
exists between trials and compassionate use in order to better develop future phage treatment
and clinical applications. The multitude of observations reported over the years in the literature
constitutes an invaluable experience, and we add to this by presenting a number of cases of patients
treated compassionately with phages throughout the past decade with a focus on osteoarticular
infections. Additionally, an abundance of scientific literature into phage-related areas is transforming
our knowledge base, creating a greater understanding that should be applied for future clinical
applications. Due to the increasing number of treatment failures anticipatedfrom the perspective of a
possible post-antibiotic era, we believe that the introduction of bacteriophages into the therapeutic
arsenal seems a scientifically sound and eminently practicable consideration today as a substitute or
adjuvant to antibiotic therapy.
Keywords: bacterial infection; antibiotic resistance; bacteriophage; antibiotic therapy; phage therapy;
cases report
1. Introduction
In 1917, Félix d’Hérelle observed a phenomenon in stool cultures from convalescent patients
with bacillary dysentery [1], which took the form of perfectly round clear areas in the bacterial lawn.
He made the assumption that these clear zones were caused by an "invisible microbe" capable of killing
bacteria, to which he gave the name bacteriophage. Two years later (1919), he demonstrated that
the oral administration of bacteriophages in humans is harmless and causes the healing of bacterial
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enteritis caused by Shigella sp. (bacillary dysentery). Based on a large number of published cases
in the years that followed, the interest and use of this new treatment in various infections spread
rapidly across the world, reaching nearly every continent [2,3]. This was the situation until the
discovery of antibiotics; when faced with their easier use, phage therapy was gradually abandoned
in Western countries until it finally disappeared completely in France with the closure in 1990 of the
elast remaining sources of therapeutic bacteriophages from the two Pasteur Institutes (Paris and Lyon).
However, phage therapy continued uninterrupted in the Soviet Union during this time and is still
practiced in Russia, Poland, Georgia and some other former Soviet States today, in accordance with
specific national regulations.
We have been witnessing the worldwide spread of multidrug-resistant (MDR) bacteria in recent
years. As new and truly innovative antibiotics are rare, the increasing frequency of therapeutic failures
are raising fears of a new pre-antibiotic era [4]. To respond to this worrying situation, the return
of phage therapy seems to be an answer not only as an alternative [5], but also a complementary
treatment, to faltering antibiotic therapy [6–8]. This renewed interest in phage therapy is manifested
by the motivation to conduct several clinical trials since 2009 that have used phages for a variety of
indications, including chronic otitis, burn wound or urinary tract infections (UTI), and Escherichia
coli diarrhea [9–12]. Indeed, phage therapy must be proven to be therapeutically effective through
experimental clinical trials in order to obtain marketing approval, which is required for use in Western
medicine. While studies have repeatedly documented its safety, it is unfortunate that no marketing
approval has been attributed to a phage product to date as a result of these resource-intensive
studies; three trials were unable to statistically prove efficacy [9,11,13], even if clinical benefit was
achieved for some patients, and the only trial that was successful has not been further pursued for
commercialization [12].
Many researchers and medical doctors have voiced the need to revise the regulatory classification
of phage therapy products in order to facilitate their clinical evaluation. Natural phages are currently
classified as Medicinal Products (MP) under European Union (EU) legislation [14] and as a drug by the
Food and Drug Administration (FDA) in the United States, which necessitate that phages be produced
under Good Manufacturing Practice (GMP) guidelines and infrastructure. While such criteria do not
completely inhibit the ability to conduct trials, they do render formal phage trials more difficult and
more expensive to conduct. Substantial financial investment is required to conduct clinical trials, and
an inconvenient amount of time is needed to procure results in order to address current clinical needs.
Phage therapy is now at a state where it is not officially recognized as a legitimate treatment,
but has been increasingly granted emergency approvals for addressing antibiotic treatment failures.
There are more than 10 published case reports [15] and a fast-growing number of undocumented
compassionate cases that report successful treatment outcomes with phage therapy. Within only the
last year, two experimental phage therapy centers have opened in addition to the long-established
Phage Therapy Unit at the Ludwik Hirszfeld Institute in Poland (Box 1). From this perspective,
and in conjunction with a century of publications on this subject for different bacterial infections
treated by phage therapy, compassionate use and case reports constitute an invaluable source of
knowledge that help to elucidate best practices for phage therapy. Many original and historical texts
published in French or Russian have been unfortunately excluded from contributing to this large body
of information and should enter into consideration. While case reports and historical accounts do not
substitute for formal clinical trials, the findings and remarks they contain are useful to set up modern
therapeutic protocols and hopefully to avoid conducting additional therapeutically-futile clinical trials.
This is what we propose to report here, both by summarizing findings from the literature and by adding
our own experience of cases, particularly for osteoarticular infections, treated under compassionate
protocols, as a means to advise on the progression of phage therapy into modern medicine.
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Box 1. Experimental phage therapy centers established in Western countries.
Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Phage
Therapy Unit in Wroclaw, Poland (IIET PAS PTU): This is the oldest and most established experimental center
in central Europe, which has been preparing phage formulations for hospital use in Poland since the 1970s,
before it became a member state of the European Union (EU). Phage therapy was and is continued under
the national regulatory framework as an experimental therapy for specific medical conditions and in specific
centers under Article 37 of the Helsinki Declaration. They have an in-house bank of phages against 15 different
bacterial pathogens (Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Serratia, Proteus, Acinetobacter,
Citrobacter, Enterobacter, Stenotrophomonas, Shigella, Salmonella, Burkholderia, Morganella). Treatment is proceeded
by phage susceptibility testing (phage typing procedure) and preparations are used for outpatient treatment.
The PTU periodically publishes summaries of their experiences [16–20] that provide factual justification for
using phage therapy and useful information for clinical applications.
Magistral preparations in Belgium (also known as a compounded prescription drug in the US) [14]. Phage
therapy can be provided as a magistral preparation in Belgium since 2018, after several years of discussion
involving public health and federal regulatory authorities, in order to facilitate physician-prescribed treatment
for individual patients. Phages are considered active pharmaceutical ingredients (APIs) that must be produced
according to an internal monograph (set of instructions) and that are subsequently certified by competent
laboratories before they are mixed or put into formulation under the supervision of a pharmacist and delivered
to a specific patient.
Center for Innovative Phage Applications and Therapeutics (IPATH) University of California San Diego,
School of Medicine: This center announced its opening in June 2018 following several successful treatments with
phage. Their first case used phage to treat an MDR systemic infection caused by Acinetobacter baumannii, which
was initiated and coordinated by the wife of the patient, a global health professor, and his physician [21,22].
While this was the first American patient with a systemic MDR infection to be successfully treated intravenous
(iv) by phage therapy, more than five patients have been treated since under the FDAs compassionate use
program and IPATH is planning to conduct clinical trials in the near future.
2. General Prerequisites for the Medical Use of Bacteriophages
Due to the unfamiliarity with and particularities of phage therapy, it is worthwhile to touch upon
several general aspects of clinical use: product availability, production, formulation and administration,
dosage, and evaluation. The permission to use phage therapy for compassionate or experimental
treatment, at the patient, physician, hospital, and health and regulatory authority levels, are beyond
the scope of this publication, but are evidently necessary to proceed with treatment and requirements
may vary country-to-country. Approvals are now often granted on an individual bases for emergency
use or in the case of antibiotic treatment failures, mostly in France, Belgium, Poland, Australia, and
the US.
2.1. Availability
The first condition for use of phage therapy is simply to have bacteriophages available for
treatment, which is often complicated at this stage of phage development. This implies having access
to phages that are both biologically active against the patient’s bacterial isolate and satisfy regulatory
requirements (purity, traceability, characterization). A single phage may be used (monophage
preparation) or several phages may be combined against one or more bacterial species (phage cocktail).
As phage therapy is not currently a recognized medicine in the West and no registered products
exist, phages are either being prepared specifically for a patient infection (personalized or custom
approach) or treatment can be done with commercial phage preparations from Russian or Georgian
suppliers, which have pre-defined phage compositions (“ready-to-use”) [23]. Such commercial
bacteriophage preparations that are available for purchase may, or may not, encounter importation
difficulties into Western countries due to product traceability or a lack of certification or analytical
information. Access can be accomplished by patients traveling to countries where phage therapy is an
approved practice (medical tourism), and the Eliava Institute in Georgia treats a number of foreign
patients onsite each year. This last option, however, is dependent upon patient mobility and financial
ability to pay for treatment.
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Alternatively, phages have been prepared for compassionate cases by small biotech and academic
institutions for individual patients. Indeed, a large number of different bacteriophages are deposited
in different collections that target clinically relevant bacteria, and it would be desirable that the
collections held in these "phage banks" organize themselves into a network to facilitate exchanges.
A networking initiative, known as the Phage Directory [24], is attempting to facilitate phage sharing
for emergency or compassionate clinical needs. If an active phage is not present or available from
such an organization, it is normally still possible to isolate one from the environment, although this is
pathogen dependent, sufficient characterization is still required, and is difficult to achieve for acute
life-threatening infections [25].
2.2. Production
Phage products must be produced with an acceptable level of purification for clinical use in
order to remove remaining endotoxin and bacterial contaminants. If phage preparations are viewed as
medicinal products, they will be subject to GMP compliance, which are standards intended to guarantee
the quality of a medicine [26]. This requires that a procedure be defined for their manufacture and
stipulates a combination of physicochemical and biological tests, as well as stringent production
facilities. The quality (i.e., the stability and consistency) of a biological drug, such as phages, is
harder to guarantee and control than that of a chemical, and GMP requirements have put a strain
on the clinical development of phage therapy in Western medicine, as well as greatly increasing
production costs. Indeed, GMP constraints both delayed patient enrollment for the Phagoburn
clinical study and negatively impacted the phage titer of the final product [9]. An adaptation of
the regulation is necessary [27–32] and, in particular, will have to take into account the use of
individualized preparations [33] as a personalized medicine [28,34], and modification of phage
components throughout treatment to counteract bacterial–phage resistance. Production considerations
must take into account the sustainability of the phage treatment approach and patient safety.
Phage therapy is currently implemented for compassionate use and individual patients by
by-passing GMP-requirements. Belgium has opted to facilitate phage therapy by presenting the phage
as magistral preparations, which are individually prepared by prescription for individual patients
by a qualified hospital pharmacist, and the quality of phage preparations are verified by accredited
laboratories (Box 1) [14]. Even without such a systematic approval system, phage biotech companies
(MicroGen, Eliava, Pherecydes Pharma, Advanced Phage Therapeutics, AmpliPhi Biosciences), as
well as academic institutions and military research institutions, have helped in the production process
and/or supply of phages for emergency use.
2.3. Formulation and Administration
The administration of a drug is dependent on the vectorization/formulation of the active phage
component [35,36]. Local application is easiest to apply, and tolerance has been repeatedly documented
for this route [9,37]. Phages may be applied topically either in cream/gel formulations or by contact
with soaked bandages on the wound surface. Bacteriophages, being of a protein nature, raise the
concern of an anaphylactic reaction following repeated administration. However, severe reactions
have only been rarely reported, and today the risk is further reduced by advanced purification
methods [38–40].
While oral administration is easy and without side effects, gastric acidity is a hostile barrier to
ingested bacteriophages. To overcome this drawbackthere are two possible approaches: alkalinisation,
by administration of an alkaline liquid (bicarbonate water, carbonated water), or gastro-resistant
vectorization (i.e., in release capsules or pills). Alkaline neutralization may come with an increased
risk of opportunistic infections for patients, and vectorization comes at an increased cost of production;
more clinical data are required to determine the best strategy for oral phage application.
Inhalation seems to be effective in delivering lyophilized bacteriophages to the lungs in the
form of powder propelled by inhalers [41]. The bronchopulmonary tree is indeed easily accessible
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by air, and thus, it is conceivable to spray bacteriophage suspensions (nebulization, misting) or dry
forms (spray) [42]. However, few cases have been published to date [43–48], and using appropriate
vectorization for inhalation remains to be evaluated.
Diffusion is rapid after systemic ie intravenous administration, though circulating phages are
sequestered by the reticuloendothelial system in the spleen and liver. In the absence of bacterial target
hosts, phages are quickly eliminated. On the contrary, if bacterial targets are present, phages multiply to
a degree dependent on a multitude of bacterial (metabolic activity, sensitivity) and mammalian factors,
making the estimation of pharmacokinetics [49] variable and difficult to estimate between patients.
2.4. Dosage
The required dosage, rhythm, and duration of treatment have been poorly studied. Theoretically,
in situ multiplication requires only one application; while in practice, repetition is often the rule.
Unlike conventional drug treatments, the pharmacological parameters are poorly defined and
understood at present, which presents the main difficulty in being unable to predict the extent of
in vivo multiplication.
2.5. Therapeutic Evaluation
Like any drug, a biomedicine must be studied experimentally to appreciate its positive and
negative effects on a living organism. Although many publications (individual cases and clinical series)
have shown positive results of phage therapy and presented few adverse effects, it is necessary to
respond to modern requirements and to carry out randomized, double-blind controlled trials [50,51].
Nonetheless, simpler hospital observational studies, despite their drawbacks and inadequacies, would
make it possible to provide highly valuable information for pressing questions while satisfying
prerequisites (i.e., the number of patients likely to be included within a defined period of time) that
have often been difficult for modern trials to achieve to date.
Many case studies today evaluate phage therapy by the most essential factor: the clinical
improvement of the patient. However, information documenting phage activity within the patient,
such as phage amplification or phage sensitivity, are often lacking, and therefore claims that phage
therapy causes clinical amelioration are not data-supported. Much more information could and should
be obtained from compassionate and emergency-use treatments to further our knowledge-base of
phage therapy in humans.
3. Clinical Indications in the Literature
Inherently, phages are able to treat any clinical presentation of bacterial infections. Reports
have been published using phage therapy for a large array of clinical indications, including
gastro-intestinal [2,11,52–54], localized [3,37,55–59], burn wound [9,60], systemic [21,39,61–72],
urogenital [10,73–82], respiratory [44,45,47,82–85], oto-rhino-laryngeal (ORL) [12,86–95], and
osteoarticular infections (see section below). These clinical indications include infections that are
acute or chronic, sensitive or resistant to antibiotics, and are caused by highly variable common or
opportunistic pathogens.
Acute systemic infections, such for septicemia or meningitis, have been treated with phages with
some success. It seems premature to consider such indications initially for phage therapy for at least
two reasons: the urgency of treatment and the need for parenteral administration. Both aspects require
readily-available, highly-purified phages, and rapid approval processes that, while not insurmountable,
are not feasible for broad implementation at this time. Indeed, the few published cases of systemic
treatments are the result of a few geographical competency centers and close collaboration between
phage researchers and clinicians.
Chronic infections, however, are increasingly frequent and have gained attention as a target for
phage therapy. Chronicity is supported by the formation of bacterial biofilms, intracellular bacterial
persisters, or tolerant bacteria that are particularly problematic for UTIs, bacterial prostatitis, prosthetic
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joint infections (PJI), osteomyelitis, and respiratory conditions such as cystic fibrosis (CF). They
require long-term antibiotic treatment that disrupts healthy microbiomes and selects for antimicrobial
resistance. Such infections, if not constantly suppressed, risk development into bacterial sepsis. CF,
although not an infectious disease itself, is the subject of special attention for phage therapy because of
the chronic state of repetitive superinfections in these patients, which are usually caused by mucosal
Pseudomonas aeruginosa strains resistant to many antimicrobials and capable of forming biofilms [96].
In addition to classical pathogens, opportunistic bacteria are often multidrug-resistant and cause
infections that are difficult to control [96], for which the question of the interest of phage therapy is
repeatedly raised. Infections with some bacteria, such as mycobacteria, present additional biological
obstacles, such as preferential intracellular location of bacteria (macrophage or epithelial cells) and
a slow growth rate, as in tuberculosis. Ready-to-use bacteriophage suspensions are generally not
available for such situations, and a few teams have looked at some of them, although it is still too early
to draw any conclusions. These include, more specifically, infections caused by Helicobacter [97,98];
Borrelia (Lyme disease [99]), as well as Brucella, Yersinia pestis and Bacillus anthracis [100] in the
context of biological-weapon risks [101]. Other bacterial species (Haemophilus influenzae, Streptococcus
pneumoniae) do not generate much interest today for phage therapy application. It should be noted
that Campylobacter bacteriophages are mainly studied in poultry farms in a preventive context rather
than therapeutically.
Osteoarticular infections are a particular form of deep-seated, localized infection that are a prime
target for phage therapy given their frequency and poor response to antibiotic therapy. The diffusion
of antibiotics into bone tissue is often mediocre and impaired by the presence of bacterial biofilms
that form in vivo at the contact between bone and prosthetic material. The recurrence and transition to
chronicity is more and more common for many reasons, including the presence of MDR bacteria. Today,
the number of post-surgical bone infections on fracture or joint prosthesis continues to increase [102].
Conventional antibiotic treatments are long and costly, with frequent repeat surgery, and sometimes
amputation is the only infection control option [103].
Phage therapy has been used very early and frequently for this type of infection, as evidenced
by many publications from Northern America [104] and in Eastern European countries [105–107].
In France, the surgeon André Raiga [66,108] made several assessments of his long experience in this
field. Clinical cases in Strasbourg, France were published in 1979, which document positive outcomes
in bone infections with phages (Box 2) [109]. A review of Soviet literature has also indicated complete
recovery from osteomyelitis using phages alone or in combination with antibiotics [110]. More recently,
two cases of PJI (Staphylococcus aureus) and one case of P. aeruginosa osteomyelitis were treated with
direct application of phages in France [111].
The potential of phage therapy to treat such post-accidental, surgical osteitis, or peri-prosthetic
joint infections is likely rooted in phage activity against bacterial biofilms and potentially against
intracellular bacteria. An experimental model [112] has demonstrated that a treatment combining
bacteriophages and antibiotics helps to dissolve biofilms with a pronounced effect on biofilms of
Staphylococcus sp. compared to those of P. aeruginosa. Indeed, there has been a very large number
of experimental studies for several years on this subject not only in vitro, but also in vivo [113,114].
While bacterial infections begin by biofilm formation on prosthetic surfaces, they can become chronic
by establishing an intracellular life-style within mammalian cells that shields them from antibiotic
treatment and then causes recurrent active infections. A recent model documented the ability of phages
to kill intracellular S. aureus [115].
All of the above provide substantial evidence that osteoarticular infections are a sound target
for phage therapy. With this logic, a budget has been attributed for a future clinical trial in France,
“Phagos,” for PJIs caused by S. aureus, which will begin as soon as GMP-compliant phage suspensions
are achieved [116]. Our experience with the compassionate treatment of oesteoarticular, as well as
other, infections is presented herein.
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Box 2. Conclusion of Lang et al. 1979 [109].
Seven orthopedic surgery cases were treated with bacteriophages between 1975 and 1976. Of the treated
patients, six were male and one was female. The age of patients ranged from 19–70 years of age. The cases
presented by authors were chronic, having exhausted the usual therapeutic arsenal, and phage was added to
other treatments in order to maximize patient benefit.
Five treatments resulted in good clinical outcomes, which was supported by radiological and bacteriological
examination. A condition was considered improved if symptoms were ameliorated and radiological examination
was positive, but problems persisted with scarring and positive bacterial cultures (one case). Treatment
failure with added phages occurred for one patient and caused a change in treatment plan, comprising first
local and general antibiotic therapy (ampicillin, cephalosporin, gentamicin), then hyperbaric oxygen therapy,
and finally surgical intervention, which ultimately resulted in a favorable outcome. In conclusion, the use
of suitable bacteriophages in the treatment of antibiotic-resistant chronic bone infections seemed to be an
interesting therapeutic alternative for authors, and the results of these cases encouraged continuation in this
therapeutic direction.
4. Compassionate Phage Use in France and at Villeneuve Saint Georges
Phage therapy was used to treat patients compassionately during the 1970s and 80s in France,
at a time when it was possible obtain suspensions of therapeutic phage for the pathogenic bacterium
of a patient from the Pasteur Institute. The clinical outcomes during this time with the treatment of
frequent, high-risk infections with phages have been summarized previously in a short paper outlining
conclusions and new indications for phage therapy (Box 3) [117]. At that time, phage therapy was
routinely performed in some hospitals, such as in Lyon, Paris, and Strasbourg. A surgical service at
the latter had published a small clinical study of seven cases and concluded that phage therapy was
promising, particularly in bone infections (Box 2) [109]. Several patients with bone infections in the
hospital of Villeneuve Saint Georges, for whom conventional treatment had failed, also benefited from
such phage therapy treatment during this time (unpublished results). However, by 1990, phage therapy
and its practice in France became impossible after phage production was ceased at the Pasteur Institute.
There followed a period of about 15 years during which phage therapy was totally inaccessible in France.
Box 3. Conclusion of Vieu et al. 1979. [117].
This article, published in French, highlighted how and why phage therapy was used in France at this
time. In particular, the growing importance of opportunistic bacteria resistant to antibiotics in infectious
pathology oriented the therapeutic applications of bacteriophages to three new areas: (1) the curative treatment
of postoperative surgical infections; (2) suppression of the infectious process during gram-negative pediatric
epidemics, caused notably by Salmonella, Klebsiella, E. coli, and Serratia, via oral phage administration; and (3)
curative treatment of chronic UTIs. The authors noted that a close collaboration between phage scientists and
clinicians was absolutely necessary to treat patients with phages, from identifying phages to following clinical
progression over time. The success of phage therapy was dependent upon verifying in vitro susceptibility prior
to treatment. If treatment failure occurred, it was attributable to low titers of the phage, pH environment of the
GI or urinary tracts, inactivation of the phage by simultaneously-prescribed local antiseptics, or the involvement
of several pathogens not identified at diagnosis outside the bacterial host range of the phage preparation. In
conclusion, the authors affirmed that phage therapy was a merited treatment option due to the frequent clinical
successes it produced.
In 2004, we were able to buy over-the-counter commercial preparations of bacteriophages from
pharmacies in Moscow for a few dozen Euros. After an evaluation (for sterility, activity, specificity) of
these preparations [118], those capable of responding to the clinical problems at hand were retained
and used. The first case we treated was a particularly worrying case of an evolving infection of the
external auditory canal, where a bacteriophage suspension against S. aureus was used to treat chronic
otitis externa (Box 4; Patient 1 in Table 1). With this experience, and in the face of the increasing
therapeutic failures that we were confronted with, especially in orthopedic surgery, some of us decided
to reintroduce phage therapy more routinely from 2008 in the hospital in which we practiced, and it is
still occasionally used as needed at the hospital of Villeneuve Saint Georges. We will briefly outline the
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process of using phages for compassionate use and present several clinicals cases of our experiences in
phage therapy.
Box 4. Treatment of an external otitis.
A young patient was examined for chronic otitis after episodes of repeated otitis treated with various
antibiotics. The specialist noted an otorrhea and decided to treat it medically (cefpodoxime and ofloxacin) before
surgery. Repair of the tympanic membrane was performed. The immediate treatment outcome was obvious:
symptoms (pain, drainage) rapidly disappeared with no complications or side effects.
After three months, the otorrhea reappeared. The examination was particularly difficult because of very
sharp local pain, as the eardrum was inflamed and wet. The resumption of local antibiotic therapy (bacitracin)
helped reduce pain. During one year, the patient experienced several treated otorrheas (ofloxacin). During
an outpatient consultation with acute pain and under general anaesthesia, a specimen was collected showing
the presence in pure culture of S. aureus (penicillin-R, methicillin-R, erythromycin-R and ofloxacin-R). Despite
antibiotic therapy being immediately prescribed (not specified), the purulent flow and pain persisted, and the
Staphylococcus was still present.
It was then decided to carry out a more precise examination and to collect multiple specimens (tympanic
membrane, cutaneous coating of the external duct) before the local application of a bacteriophage suspension,
active in vitro against the patient isolate, in combination with pristinamycin. Within 48 hours, the patient
noticed a clear improvement: the cessation of purulent flow and pain. Subsequent consultations confirmed a
favorable course: the absence of otorrhea or pain and disappearance of Staphylococcus. After three months, the
ear examination was still very satisfactory and the treatment was stopped.
5. Protocol for Compassionate Use of Phage Therapy
Before patient admission, the decision to use phage therapy is made by a multi-disciplinary
hospital team (surgeon, infectious disease specialist, microbiologist), who conduct a complete
examination of the patient and patient file. In addition to the biological assessment, one or more
preliminary specimens is taken to isolate the bacterium and test its sensitivity to available phages.
Patients are informed about phages and the possibility of treatment. Phages are administered by a
treating physician who exercises their ethical right to use an experimental treatment in the best interest
of the patient, without an elaborate regulatory or administrative framework.
During therapeutic care, if necessary, the infectious foci are excised (debridement) and cleaned
in the operating room. One or more intraoperative specimens are collected to confirm the initial
bacteriological diagnosis. At the end of surgery and before closure of the operative field, the preparation
of bacteriophages is used to flood the operative field (5 to 10 ml according to the surface of the field).
Access to the treatment site (opening or drain) allows a bacteriological control and the introduction of
the same phage preparation in the days following the intervention.
Antibiotic therapy reflecting the pathogen’s antibiotic resistance profile is used in combination
with phage therapy, and the patient is kept under surveillance for several days (less than one week) to
ensure that there was no evidence of infection (local, biological, or bacteriological). The postoperative
course has presented no complications, and no side effects have been reported.
Regarding follow-up, ambulatory monitoring is performed in our facility for several months at a
variable frequency, as deemed necessary. The evaluation of each case is performed clinically, as well as
biologically and radiologically. Some patients provide us periodically with their health status, which
so far has been excellent.
All cases reported here (Table 1) have benefited from compassionate phage therapy for the duly
recorded treatment failure. The phage therapy treatments were carried out between 2006 and 2018
after a long evolution, generally several years, of a conventional treatment according to official medical
guidelines. All patients had benefited from multiple attempts at treatment (surgical interventions and
antibiotic therapy) and had been in therapeutic failure for months or even years. Some had previously
tried treatment at the Eliava Institute in Tbilisi. All presented cases were treated in France at the
Villeneuve Saint Georges Hospital, unless otherwise noted. The authors have also been involved in the
treatment with phage therapy for a case for a refractory UTI in Australia, published previously [78].
Viruses 2019, 11, 18 9 of 21
Table 1. Summary of patients treated with compassionate use of bacteriophages from 2006–2018.
N Age;Sex
Symptom Onset;
PT Start Clinical Symptoms Bacteria Phage Therapy Outcome
1 20; F 2004;2006
Suppurating chronic otitis; intense
pain S. aureus
Commercial anti-S. aureus suspension; ear drop
instillations (15 days) 2006 Complete cure
2 44; M 2005;2008
Accidental fall; multiple fractures
(n = 37); amputation considered S. aureus
Commercial anti-S. aureus and Pyophage
suspensions; administered peroperatively over
several weeks
2009 Wound closure and complete cure
3 25; M 2007;2008
Road accident causing multiple
trauma; uncontrolled pelvic bone
infection
S. aureus
P. aeruginosa
Anti-S. aureus and anti-P. aeruginosa phage
suspension; administered peroperatively and
via catheter in days following operation
(Belgium).
2010 Complete cure
4 40; F 1995;2009
Fall leading to complex fracture of
the right foot; Planned amputation S. aureus
Commercial anti-S. aureus suspension
administered peroperatively and via catheter in
the days following operation
2009 Wound closure and complete cure
5 60; M 2008;2009
Fistulised abdominal plaque
infection; continuous suppressive
antibiotic administration
Methicillin resistant
S. aureus (MRSA)
Commercial anti-S. aureus suspension
administered via fistula
2010 No recurrence without any
antibiotic over 4 years
6 80; F 2008;2010
Knee prosthesis infection
unsuitable for surgery P. aeruginosa
Commercial broad spectrum
multi-bacteriophage suspension; Knee joint
injection
2012 P. aeruginosa clearance, but
appearance of Enterococcus sp.
7 61; F 1995/2005;2010
Operated tongue cancer; Dental
extraction, jaw fracture,
osteo-synthesis and fistulised
infection
S. aureus (MRSA) Commercial anti-S. aureus suspensionadministered peroperatively 2011 Complete cure
8 90; F 2009/2010;2010
Femoral fracture under hip
prosthesis;
Drained hematoma and
antibiotherapy-infection
S. aureus (MRSA)
Commercial anti-S. aureus suspension
administered peroperatively by flooding the
infection site and via catheter in the 10 days
following the operation
2011 Complete cure, rapid recovery
without recurrence after 1 year with
retention of the hip prosthesis and
osteosynthesis material in situ
9 20; M 2012;2012
Chronic Ulcerative Colitis with
liver complications. Severe weight
loss (54 kg down from 80 kg). Poor
digestion of food.
E. coli, Proteus spp.
S. aureus
(Urine)
S. aureus (skin)
E. coli, Proteus vulgaris,
Proteus mirabilis (stool)
Treatment in Tbilisi (Georgia) with 2
commercially available phage suspensions plus
special customised phage suspension.
Probiotics, enzymes and Camelyn immune
stimulant also given. Treatment lasted 1 month.
2012 Healing with sterilisation of urine,
reduction of E. coli and P. vulgaris growth
from high (108) to low (<102) in stool.
Weight gain to 72 kg by end of treatment.
Digestion improved but still poor
10 72; F 2009;2013 Left knee prosthesis infection Staphylococcus sp.
Commercial anti-S. aureus suspension
administered peroperatively by flooding the
infection site
2013 Initial partial disinfection with
closure of several fistula followed by
stabilisation
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Table 1. Cont.
N Age;Sex
Symptom Onset;
PT Start Clinical Symptoms Bacteria Phage Therapy Outcome
11 84; M 1943/2012;2013
Osteomyelitis of the left tibia;
Fistula next to the wound S. aureus (MRSA)
Initial phage therapy treatment in Tbilisi via
fistula with temporary improvement, followed
by surgical follow up intervention in France in
2013; Commercial anti-S. aureus suspension
administered peroperatively by flooding the
infection site
2013 Complete cure
12 58; F 2000;2013
Acoustic neuroma with
nosocomial infection of the ENT
and ophthalmic regions
S. aureus
Treatment in Tbilisi with locally produced
phage suspensions administered locally and
orally
2013 Complete cure allowing an
ophthalmic intervention of the retina
that had been delayed for several years
13 68; F 1973;2015
Operated left tibia fracture,
followed by re-opened bone
infection
2013: Travel to Phage Therapy
Center (Tbilisi)
S. aureus
Surgery, phage therapy with commercial
staphylococcal phage suspension, and
antibiotherapy
2016 Disappearance of S. aureus replaced
by P. aeruginosa & Streptococcus
constellatus, followed by complete cure
without recurrence
14 84; M 2006 & 2015;2016
Prostate adenectomy with chronic
urinary infection and bacteraemia
Extended-spectrum
beta-lacatamase E. coli
(ESBL)
Anti-E. coli phage suspension administered per
os and rectally 2018 Complete cure
15 86; M 2016;2018
Recurring prostatitis with
bacteraemia P. aeruginosa
Commercial multi-phage suspension
administered orally and rectally
2018 Complete cure with disappearance
of any urinary infection for the first time
in 2 years
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The infectious sites were predominantly osteoarticular (9/15), but also included two cases that
involved the prostate and other four various infections (two ENT, one abdominal, and one GI tract).
The predominantly targeted bacterial species was S. aureus (12/15). More rarely, P. aeruginosa (three
instances) and two instances of E. coli were the causative pathogens or were present in polymicrobial
infections. Most often, this was a mono-microbial infection (13/15). Suspensions of bacteriophages
were mainly from commercial sources (Microgen in Russia and the Eliava Institute in Georgia).
In the absence of commercially available preparations, two cases were treated with personalized
bacteriophage suspensions.
This small series of cases calls for some remarks. We found that the local application of
bacteriophages is completely safe, and no accidents or incidents have been reported. We have also
observed highly satisfactory results, and often with rapid improvement. In fact, 12/15 cases resulted in
a complete recovery (a secondary problematic pathogen emerged in one case, only a stable condition
was achieved for one patient, and one case of a GI infection improved after phage treatment, but for
which the condition was not fully resolved). The administration of bacteriophages had always been
accompanied by antibiotic therapy with the aim of obtaining a possible synergy. Note that these were
chronic cases which had exhausted the usual therapeutic resources, and whose clinical condition was
worrying with a poorly functional prognosis. The focus was not to try to experiment or optimize
phage therapy, but instead to treat patients with all available resources.
The pathologies that have been treated are varied. In our small case study, bone infections were
the most frequent and generally evolved favorably within a few weeks. If there were fistulas, they
disappeared, and bone consolidation was observed both clinically and functionally and was confirmed
by imaging. Bacterial pathogens became quickly undetectable by microbiology after phage therapy
began. After a follow-up for some patients of over 10 years, no relapse has been observed, and it
is possible to conclude that patients were completely healed. In two cases where amputation of the
lower limb was being considered, this option was avoided. Treatments that prevented the ablation of
prosthetic material were also clinically satisfying.
To emphasize the treatment of two prostatitis cases, which constitute the most recent that we have
taken care of, infections were caused by E. coli in one case and P. aeruginosa in the other. They affected
elderly people who had been undergoing antibiotic therapy for several months. Concomitant oral and
rectal administration over two consecutive days in one case and over three days for the other quickly
resolved the recurrent infectious problem.
6. Recent Knowledge to be Taken into Consideration for Phage Therapy
The number of phage-related in vitro and in vivo studies, combined with newer areas of research
such as the microbiome, has never been greater and provides a wealth of knowledge to keep in
consideration when approaching clinical application. The activity of phages against biofilms, their
ability to block bacterial receptors, and their synergy with conventional antibiotics has important
implications for clinical treatment. Beyond bacterial lysis, phages have also been shown to interact
in different ways with the immune system of the patient and their overall microbial community.
The role that phages play naturally in the microbiome ecosystem is only starting to be discovered.
Awareness and incorporation of these aspects provides a greater understanding of phage therapy and
its clinical utility.
Regarding antibacterial aspects, the most pertinent aspect of new knowledge is the exploration
of phage-antibiotic synergy (PAS). Several recent studies both in vitro [7,8,119,120] and in vivo on
numerous experimental animal models [121] have confirmed the potential of combined use by
showing the synergy of specific bacteriophage–antibiotic combinations at sometimes sub-inhibitory
doses [122,123]. This could be a function of reducing the development of bacterial clones resistant to
traditional antibiotics, by separate killing mechanisms, or other additive functions.
In almost all compassionate use cases, phages have been used in conjunction with antibiotics.
It was even shown that phage administration changed the antibiotic resistance profile during the
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treatment of an A. baumanii infection, which led to the inclusion of the antibiotic in the treatment
regimen [21]. Additionally, it has been shown [124] that, to combat S. aureus infections, the therapeutic
results can also be influenced by the sequence in which the therapeutic agents are administered: best
results were obtained when phage therapy precedes antibiotic therapy. As interesting as this effect may
be, methods for determining the best choice of phage(s) and antibiotic(s) are still lacking. Nevertheless,
the reintroduction of phage therapy deserves to be approached with the idea that it could be not only
an alternative, but also a complement, in circumstances where the diffusion of an antibiotic is weak, as
is the case in bone tissue or in the presence of a biofilm for example [6].
The activity of phages against bacterial biofilms is yet another factor in support of phage therapy.
The pathogenic role of biofilms appears fundamental in chronic infections, especially in the presence
of foreign materials (i.e., prosthesis, catheter). The proteolytic enzymes of certain bacteriophages are
capable of destroying polysaccharides in biofilms which allow bacteria to escape natural defenses and
antibiotic treatments [125]. In addition to allowing the adhesion of bacteriophages on the bacterial
surface, this action facilitates the diffusion of antibiotics. It should be noted that soluble degradation
products of S. aureus biofilm components could have a deleterious role on osteoblasts [126] and
thus limit the growth of bone callus, which would explain the rapid bone healing observed after
bacteriophage treatment observed in the compassionate cases in Table 1.
The very interaction of phages with the surface of bacterial cells may itself have an additive effect
for phage therapy. It has been shown that bacteriophages, by attaching themselves to the bacterial
surface at particular sites, could block resistance mechanisms such as an efflux pump or impair the
fitness or the virulence factor of a bacterium [127]. This would then make certain bacteria (i.e., P.
aeruginosa or K. pneumoniae) more susceptible to traditional antibiotics and facilitate the healing of
certain pathologies, such as endocarditis or vascular prosthesis infections.
Regarding the interaction with mammalian cells, facets that are directly linked to the bactericidal
effects are further complemented by a larger understanding of phage interaction with human cells
and physiology, particularly with the immune system. Studies indicate that, in addition to their
well-known antibacterial action, bacteriophages have potent immunomodulatory properties. For some
authors, the success of phage therapy, depending on the bacterial permissiveness of the phage, is
related to the immunity of the subject. In particular, for Roach et al. [46], neutrophil–bacteriophage
synergy demonstrated that it is essential for the cure of pneumonia. For Dabrowska [128], the impact
on the immune system affects the final outcome of phage therapy. While antibody induction may play
a role in eliminating bacteriophages, it has also been shown that they can induce cytokine production
in mammalian immune cells.
In reference to phages and surrounding microbiota, bacteriophages are present in all
micro-ecosystems found in nature, and their presence in human microbiota is becoming increasingly
recognized. Human microbiomes are distinct for various anatomical niches of the body (digestive tract,
vaginal cavity, mouth, airway, nares, skin, urine [129–135]) that house dense microbial communities
containing not only bacteria, archaea and fungi, but also mainly viruses, of which bacteriophages
are the majority and remain largely unexplored [135–137]. The notion of the microbiome must be
borne in mind when a bacteriophage treatment is being considered [138]. Indeed, the introduction
of a bacteriophage in a structured community is not without consequence, because it induces
difficult-to-predict interactions that may facilitate or hinder the intended effect [139]. Interactions occur
not only with the microbiome with which it comes in contact, but also eukaryotic tissue cells [140,141]
and the immune system of the host organism, as mentioned above [142]. Consequently, a model
consisting of this "ménage à trois" has been proposed and should be considered [143]. A good
knowledge of these components could help improve treatment outcomes and should make phage
therapy a more personalized therapy.
An interesting consideration of gastro-intestinal diseases is the interplay with surrounding gut
microbiota. Indeed, many gastro-intestinal diseases are increasingly described as a dysbiosis in the
microbial community rather than being caused by a discrete pathogen, and microbiome sequencing
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has been useful in revealing disease-associated microbial signatures [144,145]. Phages may be useful
in restoring a proper balance, such as for Crohn’s disease or ulcerative colitis, and a trial targeting
Enteroaggregative E. coli (EAEC) has been initiated for Crohn’s patients [146–148].
Currently in Western countries, Clostridium difficile is a major problem (regarding diarrhea and
transmission within the community), against which conventional antibiotics are ineffective. Many
authors in recent years have considered addressing this condition with bacteriophages [149–151], and
a study has shown a strong adsorption of bacteriophages on human cells in vitro that would promote
bacteriophage–bacterial interactions is important for treating such a condition [152]. Fecal microbiota
transplantations (FMT) have been shown to be effective at treating C. difficile, and, more so, filtrates of
FMT that are devoid of bacteria also retain therapeutic properties, which may be due to the presence
or modulation of phages [153].
7. Conclusions
Noting a continuing increase in bacterial resistance to antibiotics and the scarcity of new antibiotic
molecules, the World Health Organization declared in 2014 that a pre-antibiotic era was imminent [154]
and that there was an urgent need worldwide to mobilize international cooperation. In view of the risk
to public health, new strategies need to be considered without delay: phage therapy is one of the most
successful options today, if not the most successful. The advancement of phage therapy will, however,
require an entwinement of old and new, of science and medicine, of fundamental research and clinical
application, that is unparalleled in other areas of medical research. A multidisciplinary approach is
needed more than ever, bringing together microbiologists, ecologists, evolutionary biologists, infectious
disease specialists, medical doctors, and public health professionals. The growing threat of antibiotic
resistance is indeed a compelling motivation to include and evaluate as much historical, compassionate
use, and pre-clinical information as possible to increase the likelihood of the effective implementation
of phage therapy.
The limited knowledge of phages available when they were first used historically has been
complemented by a wealth of scientific studies, and yet therapy remains largely as empiric today as it
was then. Our own empirical compassionate experiences with phages have nevertheless resulted in
good clinical outcomes and have led us to conclude that phage therapy has much to offer, particularly
for osteoarticular infections. A clinical trial is now planned to treat osteoarticular infections as an
extension of our empirical findings through compassionate treatment. Such observational evidence
from individual treatments provides valuable information on how to refine treatment protocols and to
guide effective clinical practice in the future.
The use of biological rather than chemical drugs, such as phages, is new and upsets conventional
treatment paradigms. Moreover, this development is occurring in a more strictly regulated context than
in the past, where therapeutic frameworks need to be navigated and financial support is lacking. If it
is unlikely that phage therapy will ever replace antibiotic therapy, it would surely be best to combine
available antimicrobial strategies to create an effective treatment, and more research is merited in
this direction. In the interim of conclusive phage efficacy trials, compassionate use of phage therapy,
in combination with appropriate antibiotics, should be continued to maximize positive treatment
outcomes for patients suffering from antibiotic resistant or difficult-to-treat infections.
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